Oncologists work in environments shaped by evidence, protocols, experience and habit. They manage many patients and complex pathways, leaving little scope to reassess the landscape each time. That is why decision-making shortcuts are important, especially in mature markets where existing therapies are already trusted.

Emerging assets must earn their place. Teams may invest in evidence generation, medical education and pre-launch engagement, yet fail to change practice if oncologists are unsure where the asset belongs, who it is for or when to use it.

Commercial success hinges on a clear heuristic for identifying the first appropriate patient: when I see this type of patient, this treatment should be part of the conversation.

Broader use begins with a rule of thumb supporting quick, informed prescribing. It should make the product’s role easy to recognise and recall when the right patient presents.

The first appropriate patient is the practical expression of that heuristic. Teams must pinpoint where the therapy offers the clearest clinical and practical value and where early use feels most intuitive. The most effective commercial strategies should therefore reduce uncertainty around the first prescribing decision.

Strong heuristics are grounded in the patient’s clinical context and reflect the full patient and physician experience: quality of life, treatment burden, access and affordability, adverse-event management and fit within clinical practice. Patients are not interchangeable data points. When efficacy differences are modest, improved patient support, easier access pathways, reduced monitoring requirements or a better treatment experience can significantly influence prescribing behaviour. Without these realities, better-known treatments may continue to dominate.

A heuristic gives oncologists confidence they are selecting the therapy for the right patient in the right clinical context. This lowers the barrier to an initial prescription by making the decision feel more intuitive and grounded. When that first experience reinforces the heuristic through the expected clinical outcome and a positive patient-physician experience, it builds confidence to prescribe again. Repeated positive experiences can strengthen the heuristic and help the therapy move from a novel option to an established choice.

This progression matters for forecasting, investment and commercial planning. Assumptions that overlook ingrained prescribing habits can overestimate adoption speed. Teams may need to model a staged trajectory, with use developing gradually before extending to a broader patient cohort.

Developing a prescribing heuristic should begin early and remain central throughout commercial planning. It requires coordination across commercial, medical and market access teams, and should inform positioning, segmentation, evidence generation, forecasting, field enablement and post-launch learning. During brand planning and market research, teams should test what shapes prescribing in practice.

Brand leads should ask: “When an oncologist sees a specific patient, what makes our therapy the obvious treatment to consider?” A vague or difficult-to-communicate answer may hinder adoption; a distinctive answer grounded in clinical reality makes routine use more likely.

In competitive oncology landscapes, adoption starts with a heuristic that makes the product’s role clear, memorable and actionable. Defining the cue that brings the treatment to the fore for the first appropriate patient is a pivotal commercial judgement, because it sets the direction for what follows.

Teams acting too late risk reaching launch with robust evidence and high awareness, but too little influence over the first prescribing decision. Evidence gives oncologists a reason to believe. A strong heuristic turns that belief into the confidence to choose. And in the battle for adoption, that confidence often matters more than the data.